Drugs / 68Ga-N188
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05593107 | Aug 2022 → Jul 2025 overdue | neoplasm | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-N188 | “68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.” NCT05593107 ↗ |
| Modality | Diagnostic / imaging agent | “The aim of this study was to evaluate the feasibility of nectin-4-targeted PET imaging with 68Ga-N188 as a noninvasive method to quantify membranous nectin-4 expression in...” PMID 38719240 ↗ May 2024 |
| Route | Intravenous | “68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.” NCT05593107 ↗ |